Bioray Biotechnology Named to 'Future Healthcare 100 – Top 100 Innovative Pharma Companies 2020-2021'

Shanghai, April 21, 2021 /PRNewswire/ -- Recently, the "5th Future Healthcare 100" Conference, themed "The Computation of Life," grandly opened in Wujiang, Suzhou. The organizer is VCBeat.OfficialReleased the Fifth Edition of the Future Healthcare Top 100 Series Rankings,Shanghai BRL MedicineHonored as one of the “Top 100 Future Healthcare Companies” for 2020–2021, driven by outstanding industry influence, sustained innovation, and high growth potential.·Top 100 Innovative Pharmaceuticals List.

Award Ceremony

The Future Healthcare Top 100 List (hereinafter referred to as VB100), jointly launched by VCBeat and Eggshell Research Institute, is the first list in China targeting non-listed companies in the innovative healthcare sector. It aims to select Chinese innovative enterprises that truly represent the future of healthcare, identify the core forces driving China’s future healthcare industry, and promote innovation and transformation within the healthcare sector.

Mr. Xi Zaixi, CEO of BRL Medicine, stated: “BRL Medicine’s inclusion in this selection list reflects our comprehensive strength in the innovative R&D and translational operations of core technologies. It also signifies that the innovation and future development potential demonstrated by BRL Medicine have gained recognition and affirmation from various sectors of the industry. Since its establishment, BRL Medicine has maintained a global perspective, strategically positioning itself across the gene therapy and cell therapy fields, and has achieved notable accomplishments and honors in the current stage. Looking ahead, BRL Medicine will remain committed to technological innovation, striving to address core challenges and critical technical bottlenecks in gene and cell therapy. Furthermore, we will sustain our comprehensive competitiveness through multidimensional efforts in global translation, business model innovation, brand management, strategic partnerships, and public relations, thereby bringing hope to more patients with genetic and oncological diseases and contributing to the well-being of humanity.”

Deep Cultivation: BRL Medicine Empowers the Development of Oncology and Genetic Disease Fields

Thalassemia (abbreviated as "thalassemia")Thalassemia is the most widely distributed and prevalent monogenic genetic disorder globally, with β-thalassemia and α-thalassemia being the most common forms. Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the only curative treatment for β-thalassemia; however, it is prohibitively expensive and finding a matched donor is extremely difficult. Gene therapy, with its potential for “one-time treatment leading to lifelong cure,” has brought new hope to these patients.The gene therapy currently being developed through the collaboration between BRL Medicine and Xiangya Hospital of Central South UniversityTwo patients with severe β-thalassemia have been cured and discharged, remaining transfusion-independent for over 10 months. Their total hemoglobin levels have all returned to the normal range, and they are currently under follow-up observation.It is worth mentioning that this marks the first time in Asia that thalassemia has been treated using gene-editing technology, and alsoWorld's FirstSuccessful Case of Treating β0/β0-Type Severe Thalassemia with CRISPR Gene Editing Technology. This Event Also Represents a Breakthrough Achievement in Clinical Research of Gene Editing Therapy in China.

Non-Hodgkin LymphomaIt is a hematologic malignancy originating in lymphoid tissue, accounting for 80%-90% of all lymphomas. Although patients often achieve remission after initial treatment, relapse frequently occurs subsequently. While CAR-T products have been approved for the clinical treatment of relapsed/refractory non-Hodgkin lymphoma, overall efficacy remains limited; however, studies suggest that inhibiting the PD-1 pathway may yield better clinical outcomes. Leveraging its proprietary Quikin CAR-T™ platform technology, BRL Medicine has developed a CAR-T product through a one-step preparation process without the use of viral vectors.Multiple patients receiving BRL Medicine's non-viralRapid Complete Remission Achieved After PD1-Site-Integrated CD19 CAR-T Cell Therapy.This isWorld's FirstCAR-T Therapy with Site-Specific Integration at the PD1 Locus via Gene Editing: The World’s First Clinical Trial of Non-Viral, Site-Specifically Integrated CAR-T Cell Therapy for Lymphoma

Empowering the Industry: Exploring New Models in the Gene and Cell Therapy Sector

Since its establishment, BRL Medicine has been committed to exploring new models in the gene and cell therapy industry. In its early stages, the company leveraged its independent R&D center to co-establish the “Shanghai Gene Editing and Cell Therapy Research Center” with East China Normal University, rapidly advancing the deep integration of industry, academia, and research. Over the past five years, it has generated 120 domestic and international patents, forming a globally radiating patent portfolio, and has published in renowned international academic journalsNature Biotechnology、Nature Medicine、Nature Cell Biology、Cell ResearchHaving published numerous academic papers, particularly with successive breakthroughs in the development of single-base editing tools, this work has provided new directions and tools for basic research and the treatment of genetic diseases such as β-thalassemia.

Meanwhile, BRL Medicine has successfully established its baseDue to the gene editing technology innovation platform and hematopoietic stem cell platform, non-viralCAR-T (Quikin CAR-T) Platform, Universal Cell Platform, Enhanced CAR-T Platformfive major technology platforms with independent intellectual property rights, along with a 6,000-square-meter GMP pilot-scale base and an operations team of over 100 professionals, efficiently ensuring the rapid translation and implementation of projects.